A prospective study of abiraterone and enzalutamide in castration-resistant prostate cancer

Trial Profile

A prospective study of abiraterone and enzalutamide in castration-resistant prostate cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Feb 2017

At a glance

  • Drugs Abiraterone (Primary) ; Enzalutamide (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Feb 2017 Results presented at the 2017 Genitourinary Cancers Symposium
    • 05 Aug 2016 New trial record
    • 07 Jun 2016 Results of expanded analysis of the Johns Hopkins cohort presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top